Want to see SE:CARE full AI Analyst Report?
Top Page
Careium AB
(CARE)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr29.00
▲(0.69% Upside)
Action:Reiterated
Date:07/11/26
The score is driven primarily by improving financial fundamentals (return to profitability, resumed TTM revenue growth, and positive free cash flow) and a strong upward technical trend (price above major moving averages with positive MACD). These positives are moderated by margin compression versus 2024, weaker cash conversion, and a valuation that looks demanding at a 22.2 P/E without a stated dividend yield.
Positive Factors
Profitability recovery and renewed revenue growth
The return to positive earnings alongside renewed revenue growth indicates that Careium’s turnaround is gaining operational traction. A solid gross margin provides room to support services and reinvestment, while continued sales expansion could improve earnings power if profitability stabilizes over the coming quarters.
Negative Factors
Sustained margin compression
Margin deterioration despite renewed revenue growth suggests that cost pressure or an unfavorable mix is reducing the benefit of higher sales. If this persists, Careium may generate less profit from each customer and have fewer resources available for technology investment, service improvements, or balance-sheet strengthening.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability recovery and renewed revenue growth
The return to positive earnings alongside renewed revenue growth indicates that Careium’s turnaround is gaining operational traction. A solid gross margin provides room to support services and reinvestment, while continued sales expansion could improve earnings power if profitability stabilizes over the coming quarters.
Read all positive factors
Careium AB (CARE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr654.38M
Dividend YieldN/A
Average Volume (3M)9.40K
Price to Earnings (P/E)18.5
Beta (1Y)0.45
Revenue Growth8.98%
EPS Growth-16.41%
CountrySE
Employees602
SectorGeneral
Sector StrengthN/A
IndustrySecurity & Protection Services
Share Statistics
EPS (TTM)1.53
Shares Outstanding24,326,214
10 Day Avg. Volume7,649
30 Day Avg. Volume9,404
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.85
Price to Sales (P/S)0.68
P/FCF Ratio11.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.09
Revenue Forecast (FY)kr971.30M
Careium AB Business Overview & Revenue Model
Company Description
Careium AB (Publ), established in 1974 and headquartered in Malmö, Sweden, specializes in providing technologically advanced care solutions across numerous European nations, including Sweden, Norway, the United Kingdom, and the Netherlands. Their ...
How the Company Makes Money
Careium makes money by selling and supporting telecare offerings that combine hardware and ongoing service delivery. Revenue is typically generated through: (1) service fees for operating telecare solutions, which can include hosting/operating the...
Careium AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 915.50M | 854.10M | 870.70M | 824.60M | 725.10M | 587.50M |
| Gross Profit | 396.90M | 375.10M | 373.70M | 340.50M | 273.70M | 240.30M |
| EBITDA | 132.10M | 120.60M | 150.60M | 137.90M | 67.90M | 65.10M |
| Net Income | 38.00M | 35.80M | 58.40M | 37.90M | -8.60M | 4.70M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.09B | 1.05B | 961.40M | 992.10M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 40.30M | 54.90M | 31.90M | 31.50M | 39.90M | 142.50M |
| Total Debt | 206.70M | 209.70M | 196.80M | 225.30M | 322.70M | 292.30M |
| Total Liabilities | 394.10M | 407.40M | 371.40M | 361.90M | 425.50M | 500.20M |
| Stockholders Equity | 717.20M | 681.50M | 678.20M | 599.50M | 566.60M | 551.50M |
Cash Flow | ||||||
| Free Cash Flow | 64.50M | 51.30M | 36.90M | 61.90M | -87.10M | -70.90M |
| Operating Cash Flow | 137.70M | 143.40M | 92.90M | 111.90M | -21.10M | -19.80M |
| Investing Cash Flow | -102.40M | -102.20M | -56.00M | -50.00M | -68.70M | -163.70M |
| Financing Cash Flow | -30.00M | -13.70M | -39.60M | -69.70M | -15.10M | 291.00M |
Careium AB Technical Analysis
Positive
28.80
Price Trends
28.42
Negative
27.57
Positive
24.81
Positive
Market Momentum
-0.36
Negative
55.86
Neutral
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Positive. The current price of 28.8 is above the 20-day moving average (MA) of 27.51, above the 50-day MA of 28.42, and above the 200-day MA of 24.81, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 55.86 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CARE.
Careium AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr654.38M | 18.50 | ― | ― | 8.98% | -16.41% | |
62 Neutral | kr544.58M | 13.50 | ― | 3.22% | -3.29% | 3.21% | |
58 Neutral | kr108.42M | 13.90 | ― | 1.42% | 3.50% | 58.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | kr160.66M | -1.68 | ― | ― | -14.52% | -18.45% | |
45 Neutral | kr87.37M | -23.22 | -58.52% | 1.06% | -10.60% | 98.81% |
* General Sector Average
SE:CARE
Careium AB
28.30
5.00
21.46%
SE:MVIR
Medivir AB
1.69
0.26
18.07%
SE:BOUL
Boule Diagnostics AB
2.41
-2.47
-50.61%
SE:NNH
New Nordic Healthbrands AB
17.65
-5.77
-24.63%
SE:DEDI
Dedicare AB
54.40
9.30
20.61%
SE:PTRK
Physitrack Limited
9.78
-8.82
-47.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.